Navigation Links
Nektar Therapeutics Presents Positive Data from Human Abuse Liability Study for NKTR-181, a First-in-Class Investigational Opioid to Treat Chronic Pain, at 2013 Annual Meeting of The College on Problems of Drug Dependence
Date:6/19/2013

pain.  The NKTR-181 Phase 2 study is a double-blind, placebo-controlled, randomized withdrawal study design evaluating the investigational drug candidate in patients with moderate to severe chronic pain from osteoarthritis of the knee.  Approximately 200 patients will be randomized to receive either NKTR-181 or placebo in the study.

NKTR-181 is an NCE (new chemical entity) which was created using Nektar's proprietary small molecule polymer conjugate technology and its potential differentiating properties are inherent to its molecular design.  In June of 2012, the U.S. Food and Drug Administration (FDA) granted Fast Track Designation to NKTR-181 for the treatment of moderate to chronic pain.

A Phase 1 clinical program for NKTR-181 has been completed in approximately 160 healthy volunteers.  These studies showed that NKTR-181 produced sustained and dose-dependent analgesic responses with twice-daily dosing over a period of 8 days.  These studies also measured the contraction of pupils over time following dosing with NKTR-181 and the data confirmed that NKTR-181 has a slow rate of entry into the CNS (central nervous system).  This slow rate of entry is designed to reduce the euphoria that can lead to abuse and addiction to current opioid analgesics.1 

Analyst Call to be Held 10:00 AM Pacific Time/1:00 PM Eastern Time on Wednesday, June 19, 2013The company will be hosting a call to discuss these data with analysts and investors at 10:00 AM Pacific time/1:00 PM Eastern time today.  Hosting the call will be Howard Robin, President and CEO of Nektar, and Robert Medve, MD, Chief Medical Officer.  Joining company management will be Sidney H. Schnoll, MD, PhD of PinneyAssociates, an internationally recognized expert in addiction and pain management. 

A live audio-only Webcast of the conference call c
'/>"/>

SOURCE Nektar Therapeutics
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related medicine technology :

1. Nektar Presents Positive Preclinical Data for NKTR-214, a Novel Cancer Immunotherapy, At the 2013 American Society of Clinical Oncology Annual Meeting
2. Nektar Presents Target-Specific Biomarkers Being Assessed in Ongoing Phase 3 BEACON Study of Etirinotecan Pegol for the Treatment of Metastatic Breast Cancer at the 2013 American Society of Clinical Oncology Annual Meeting
3. Nektar Therapeutics President and CEO, Howard W. Robin, To Present at the Jefferies 2013 Global Healthcare Conference in New York City
4. Nektar Therapeutics President and CEO, Howard W. Robin, To Present at the 2013 UBS Global Healthcare Conference in New York City
5. Nektar Therapeutics Reports Financial Results for the First Quarter of 2013
6. Nektar to Announce Financial Results for the First Quarter of 2013 on Thursday, May 9, 2013, After Close of U.S.-Based Financial Markets
7. Nektar Therapeutics to Present at the 33rd Annual Cowen and Company Healthcare Conference in Boston
8. Nektar Therapeutics Reports Fourth Quarter and Year-End 2012 Financial Results
9. Nektar To Host Conference Call To Discuss The Positive Phase 3 Clinical Results For Naloxegol
10. Nektar Announces that FDA Grants Fast Track Designation to Etirinotecan Pegol (NKTR-102) for the Treatment of Metastatic Breast Cancer
11. Nektar to Announce Financial Results for the Third Quarter of 2012 On Tuesday, November 13, 2012, After Close of U.S.-Based Financial Markets
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/20/2014)... , Aug. 20, 2014 Reportlinker.com ... available in its catalogue: The Market ... http://www.reportlinker.com/p02051938/The-Market-for-Medical-Devices-in-EMEA .html The European, Middle Eastern and ... medical devices. As part of its coverage, this ... concentrates on the EMEA medical device markets and ...
(Date:8/20/2014)... Aug 20, 2014 Reportlinker.com announces that ... its catalogue: Global Patient Scales Industry ... This report analyzes the worldwide markets for Patient ... Segments: Floor Scales, Infant & Baby Scales, Chair ... separate comprehensive analytics for the US, Canada, Japan, ...
(Date:8/20/2014)... 20, 2014 Glenmark Pharmaceuticals ... Pharmaceuticals Limited India (GPL), announces the discovery and ... clinical development candidate, GBR 1302, a HER2xCD3 bispecific ... the Glenmark Biologics Research Centre located in La ... is based on Glenmark,s innovative BEAT antibody technology ...
Breaking Medicine Technology:The Market for Medical Devices in EMEA 2The Market for Medical Devices in EMEA 3The Market for Medical Devices in EMEA 4The Market for Medical Devices in EMEA 5Global Patient Scales Industry 2Global Patient Scales Industry 3Global Patient Scales Industry 4Global Patient Scales Industry 5Global Patient Scales Industry 6Global Patient Scales Industry 7Global Patient Scales Industry 8Global Patient Scales Industry 9Global Patient Scales Industry 10Global Patient Scales Industry 11Global Patient Scales Industry 12Global Patient Scales Industry 13Global Patient Scales Industry 14Global Patient Scales Industry 15Global Patient Scales Industry 16Global Patient Scales Industry 17Global Patient Scales Industry 18Global Patient Scales Industry 19Glenmark Enters Oncology With the Discovery and Initiation of IND Enabling Studies of an Innovative Bispecific Antibody 2Glenmark Enters Oncology With the Discovery and Initiation of IND Enabling Studies of an Innovative Bispecific Antibody 3
... Risk Frontline Elderly AML and in Combination with Cytarabine in Relapsed/Refractory ... for Tuesday, December 9 at 11:00 am ET to Discuss Phase ... , SAN FRANCISCO , Dec. 7 Sunesis ... of new data from two ongoing clinical trials demonstrating that the ...
... Dec. 6 Results from RESTORE 2, a,placebo-controlled, Phase ... the number of seizures in adult,patients with refractory partial-onset ... added to a patient,s current anti-epileptic drug (AED) therapy. ... experiencing,seizures despite taking stable doses of up to three ...
Cached Medicine Technology:Sunesis Pharmaceuticals Announces Presentation of Voreloxin Clinical Data in Patients with Acute Myeloid Leukemia at the 50th Annual Meeting of the American Society of Hematology 2Sunesis Pharmaceuticals Announces Presentation of Voreloxin Clinical Data in Patients with Acute Myeloid Leukemia at the 50th Annual Meeting of the American Society of Hematology 3Sunesis Pharmaceuticals Announces Presentation of Voreloxin Clinical Data in Patients with Acute Myeloid Leukemia at the 50th Annual Meeting of the American Society of Hematology 4Sunesis Pharmaceuticals Announces Presentation of Voreloxin Clinical Data in Patients with Acute Myeloid Leukemia at the 50th Annual Meeting of the American Society of Hematology 5Sunesis Pharmaceuticals Announces Presentation of Voreloxin Clinical Data in Patients with Acute Myeloid Leukemia at the 50th Annual Meeting of the American Society of Hematology 6Retigabine Significantly Reduces the Number of Seizures in Adults With Inadequately Controlled Partial-Onset Epilepsy 2Retigabine Significantly Reduces the Number of Seizures in Adults With Inadequately Controlled Partial-Onset Epilepsy 3Retigabine Significantly Reduces the Number of Seizures in Adults With Inadequately Controlled Partial-Onset Epilepsy 4Retigabine Significantly Reduces the Number of Seizures in Adults With Inadequately Controlled Partial-Onset Epilepsy 5
(Date:8/21/2014)... 2014 Teen substance abuse is long been ... The rising numbers of young adults falling victim to a ... a difference in the community, the new Troubled Teens Boca ... teens seeking to overcome something like teenage alcohol abuse ... teens find the best teen recovery facility to focus on ...
(Date:8/21/2014)... Drake University’s Phi Gamma Delta (FIJI) and Colleen’s ... research, according to Billy Cundiff, President of Colleen’s Dream ... the Cleveland Browns, says the money raised by the ... Foundation and will fund research to be conducted by ... of Gynecologic Oncology at the University of Iowa’s Holden ...
(Date:8/21/2014)... 21, 2014 Today, Fecbek.com, a leading ... new designs of wedding dresses. And all these elegant, ... designed by excellent designers. , A wedding dress or ... during a wedding ceremony. Color, style and ceremonial importance ... culture of the wedding participants. In order to satisfy ...
(Date:8/20/2014)... Skmen.com, the popular online supplier of men’s and ... party dresses online. Along with this, the company has ... all the fresh products are offered with great discounts and ... special offer before August 31. , Skmen.com has more ... A large proportion of its clothes are selling well in ...
(Date:8/20/2014)... NJ (PRWEB) August 21, 2014 ... Practitioners, today announced that Ethan Nadelmann, JD, PhD, ... Dr. Nadelmann is the founder and executive director ... in the United States promoting alternatives to the ... drug policy reform, both domestically and internationally, he ...
Breaking Medicine News(10 mins):Health News:New Helpline Provides Hope for Troubled Teens in Boca Raton 2Health News:Drake University’s Phi Gamma Delta (FIJI) and Colleen’s Dream Foundation Donate $10,000 to the University of Iowa’s Holden Cancer Center to Fight Ovarian Cancer 2Health News:Drake University’s Phi Gamma Delta (FIJI) and Colleen’s Dream Foundation Donate $10,000 to the University of Iowa’s Holden Cancer Center to Fight Ovarian Cancer 3Health News:Elegant Wedding Dresses Are for Sale at Fecbek.com 2Health News:Skmen.com: New Designs Of Mini Party Dresses Provided Online 2Health News:PAINWeek Welcomes Ethan Nadelmann, JD, PhD, as Keynote Speaker at 2014 Conference 2
... ANTONIO - Breast cancer is a multifaceted disease requiring ... adjuvant therapies. Data presented at the CTRC-AACR San Antonio ... Hormone Supplements Reduce Death from Breast Cancer , ... have been implicated in increased rates of breast cancer, ...
... are victorious in sham SEIU vote , Less ... while caregivers file over 125,000 protests , ... in a statewide vote of healthcare workers conducted by the ... workers overwhelmingly oppose their national union,s sham election. Ballots were ...
... shows , , FRIDAY, Dec. 12 (HealthDay News) -- ... their breast cancer returning after surgery may make ... difficult, a new study concludes. , Doctors typically ... on a standard risk-assessment tool, with four different ...
... just announced her resignation as President of the Texas Medical ... power by the TMB against good physicians. Kalafut,s tenure ... and stonewalling by the TMB and Governor Rick Perry. , ... said AAPS Executive Director Jane Orient. "AAPS has received ...
... for America,s Health (TFAH) commends the Institute of Medicine for their ... Century: Charting a New Course for a Healthier America ... federal government is responsible for protecting the health of Americans, but ... fixed," said Jeff Levi, PhD, Executive Director of TFAH. "The ...
... 12th annual holiday gala The,Teddy Bear Ball, The ... Steve,Mosko, President of Sony Pictures Television in recognition ... with special needs. Grammy(R),winning singer-songwriter Kenny Loggins electrified ... Heart. Long standing friend and colleague of,nearly 30 ...
Cached Medicine News:Health News:Patient management: Quality of life and beyond 2Health News:Free Choice? Not For SEIU Members in California 2Health News:Risk Info for Breast Cancer Patients Too Confusing 2Health News:AAPS Applauds the Resignation of TMB President Roberta Kalafut, Mari Robinson Should Resign Next 2Health News:Trust for America's Health Applauds New IOM Report on Improving the U.S. Department of Health and Human Services for the 21st Century 2Health News:The Help Group's Teddy Bear Ball Salutes Sony Pictures Television President, Steve Mosko and Features Performance by Kenny Loggins 2
... Freedom leg bags are part ... a versatile line of leg bags, ... the varied needs of our customers. ... several sizes, and constructed of 100% ...
... are part of the Freedom Urinary ... leg bags, kits, and accessories designed ... our customers. These leg bags are ... of 100% latex-free soft, textured medical ...
... line of Personal Catheters® ... you would choose for ... configurations - standard, antibacterial, ... - are based on ...
The Antibacterial Personal Catheter® features a unique silicone composition that provides an antibacterial coated soft outer layer of silicone combined with a firm inner layer....
Medicine Products: